DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20195585

Cost variation analysis of hypolipidemic drugs currently available in Indian pharmaceutical market

Divyesh B. Sondarva, Hiren N. Hirpara

Abstract


Background: Indian pharmaceutical industry is one of the growing pharmaceutical markets in the world having number of formulations available with large difference in prices. Price variations of such drugs which are used by large number of population have major economical implication. Hyperlipidemia is major risk factor for ischaemic heart diseases. So we planned this study to find out variation in cost of oral hypolipidemic drugs available in India either as a single drug or as fixed dose combination (FDCs) and to compare cost of their generic version with brands.

Methods: The prices of single and FDCs of hypolipidemic drugs were taken from “Indian Drug Review 2018” and “Current Index of Medical Specialities during October 2018 to December 2018”. Maximum and minimum prices of various hypolipidemic drugs of same strength and dosage forms manufactured by different companies were taken.

Results: Minimum cost variations are 3.62% (pravastatin 10 mg) and 3.37% (rosuvastatin 5 mg and fenofibrate 67 mg). Maximum cost variations are 500% (simvastatin 5 mg) and 500.32% (atorvastatin 10 mg and fenofibrate 160 mg). Wide variations are found in cost of brand drug with generic version of same strength components. None of the pharmaceutical companies are selling drugs cheaper than or equal to the cost of generic drugs of same strength.

Conclusions: Most of hypolipidemic drugs should come under control of Drug Price Control Order so that financial burden of healthcare services on Indian population can be reduced and by adherence to treatment will improve health status of the community.


Keywords


Cost variation, Hyperlipidemia, Statins

Full Text:

PDF

References


Sundaram VM. Pharma industry in India. Drug News Perspect. 2008;21(1):59-63.

Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. J Inst Med. 2006;28(3):35-8.

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-701.

Hypolipidemic Drugs. Tripathi KD (ed). Essentials of Medical Pharmacology. Volume 8. New Delhi: Jaypee Brothers Medical Publishers Pvt. Limited; 2019: 682-693.

Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151-67.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:285–350.

National Pharmaceutical Pricing Authority, Government of India. Available at http://www.nppaindia.nic.in/DPCO2013.pdf. Accessed on 19 Nov 2019.

National Pharmaceutical Pricing Authority, Government of India, Current Price list. Available at: http://www.nppaindia.nic.in/en/homelinks/ceiling-price-of-scheduled-formulations/. Accessed 19 Nov 2019.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort-Hasen K (eds). A Textbook of Clinical Pharmacy Practice. 1st Edition. Himayatnagar, Hyderabad: Orient Longman; 2004: 72-73.

Vutukuru P, Tekulapally K. Analysis of cost variation among various Statin preparations available in India. Indian J Pharm Pharmacol. 2019;6(1):14-7.

Mamatha KR, Vishnu K. Cost variation analysis of various brands of oral hypolipidemic drugs available in Indian Pharmaceutical Market. Int J Res Pharmacol Pharmacotherapeutics. 2017;6(3):381-8.

Bhandari PR. Analysis of cost variation of hypolipidemics drugs. J Pharmaceut Biomed Sci. 2009;9(4):35-42.

Chandrappa S, Rajarathna K. Cost variation analysis of various brands of topical eye preparations currently available in Indian pharmaceutical market. Int J Basic Clin Pharmacol. 2018;7(12):2364-7.

Allisabanavar SA, Narayana Reddy S. Cost variation analysis of various brands of anti-epileptic drugs currently available in Indian pharmaceutical market. Int J Basic Clin Pharmacol. 2017;6(7):1666-9.

Frazier LM, Brown JJ, Divine GW. Can Physician education lower the price of prescription drugs? A prospective control trial. Ann Int Med. 1991;115:116-21.